Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

• Verfasst von: Dietz, Julia [VerfasserIn]
• Verfasst von: Rupp, Daniel [VerfasserIn]
• Verfasst von: Susser, Simone [VerfasserIn]
• Verfasst von: Vermehren, Johannes [VerfasserIn]
• Verfasst von: Peiffer, Kai-Henrik [VerfasserIn]
• Verfasst von: Filmann, Natalie [VerfasserIn]
• Verfasst von: Bon, Dimitra [VerfasserIn]
• Verfasst von: Kuntzen, Thomas [VerfasserIn]
• Verfasst von: Mauss, Stefan [VerfasserIn]
• Verfasst von: Grammatikos, Georgios [VerfasserIn]
• Verfasst von: Perner, Dany [VerfasserIn]
• Verfasst von: Berkowski, Caterina [VerfasserIn]
• Verfasst von: Herrmann, Eva [VerfasserIn]
• Verfasst von: Zeuzem, Stefan [VerfasserIn]
• Verfasst von: Bartenschlager, Ralf [VerfasserIn]
• Verfasst von: Sarrazin, Christoph [VerfasserIn]
• Titel: Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy
• Verf.angabe: Julia Dietz, Daniel Rupp, Simone Susser, Johannes Vermehren, Kai-Henrik Peiffer, Natalie Filmann, Dimitra Bon, Thomas Kuntzen, Stefan Mauss, Georgios Grammatikos, Dany Perner, Caterina Berkowski, Eva Herrmann, Stefan Zeuzem, Ralf Bartenschlager, Christoph Sarrazin
• E-Jahr: 2016
• Jahr: June 9, 2016
• Fussnoten: Gesehen am 08.05.2020
• Titel Quelle: Enthalten in: PLOS ONE
• Ort Quelle: San Francisco, California, US : PLOS, 2006
• Jahr Quelle: 2016
• Band/Heft Quelle: 11(2016,6) Artikel-Nummer e0156731, 17 Seiten
• ISSN Quelle: 1932-6203
• DOI: doi:10.1371/journal.pone.0156731
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Chronic hepatitis
• Sach-SW: Cirrhosis
• Sach-SW: Hepatitis C virus
• Sach-SW: Multivariate analysis
• Sach-SW: Polymerase chain reaction
• Sach-SW: Protease inhibitor therapy
• Sach-SW: Proteases
• Sach-SW: Viral load
• K10plus-PPN: 1697742564

Abstract

Triple therapy of chronic hepatitis C virus (HCV) infection with boceprevir (BOC) or telaprevir (TVR) leads to virologic failure in many patients which is often associated with the selection of resistance-associated variants (RAVs). These resistance profiles are of importance for the selection of potential rescue treatment options. In this study, we sequenced baseline NS3 RAVs population-based and investigated the sensitivity of NS3 phenotypes in an HCV replicon assay together with clinical factors for a prediction of treatment response in a cohort of 165 German and Swiss patients treated with a BOC or TVR-based triple therapy. Overall, the prevalence of baseline RAVs was low, although the frequency of RAVs was higher in patients with virologic failure compared to those who achieved a sustained virologic response (SVR) (7% versus 1%, P = 0.06). The occurrence of RAVs was associated with a resistant NS3 quasispecies phenotype (P<0.001), but the sensitivity of phenotypes was not associated with treatment outcome (P = 0.2). The majority of single viral and host predictors of SVR was only weakly associated with treatment response. In multivariate analyses, low AST levels, female sex and an IFNL4 CC genotype were independently associated with SVR. However, a combined analysis of negative predictors revealed a significantly lower overall number of negative predictors in patients with SVR in comparison to individuals with virologic failure (P<0.0001) and the presence of 2 or less negative predictors was indicative for SVR. These results demonstrate that most single baseline viral and host parameters have a weak influence on the response to triple therapy, whereas the overall number of negative predictors has a high predictive value for SVR.